Biocon Limited (BIOCON) reported its Q2 FY27 results, showing a 2% increase in revenue to ₹4,423 Cr compared to ₹4,389 Cr in the same period last year. The company’s EBITDA margin, however, declined to 20% from 22% in Q2 FY26. The focus remains on translating growth into improved margins, free cash flow, debt reduction, and higher returns on capital.

Biosimilars Performance

The Biosimilars segment recorded revenue of ₹2,809 Cr, up 3% YoY. EBITDA stood at ₹623 Cr with a 22% margin. The segment’s performance was impacted by the timing of revenue recognition on certain shipments. The 10-year Pertuzumab partnership in Brazil provides long-term revenue visibility.

Generics Segment

The Generics segment saw a 10% YoY revenue growth to ₹774 Cr. EBITDA margin expanded by over 700bps YoY to 8%. Liraglutide is gaining traction across markets, strengthening the complex injectables portfolio.

Services Division

The Services division revenue stood at ₹833 Cr, up 13% QoQ. EBITDA margin improved by 500bps QoQ to 20%. The division expects further improvement in the second half of the fiscal year.

Source: NSE Corporate Announcement

Fundamental & Technical Analysis of Biocon Limited

Biocon Limited belongs to the Healthcare › Biotechnology sector. Here’s a quick read on where the business and the stock stand today.

Biocon drops 20.1% over three months and trades near its 52-week lows. Razor-thin margins below 5% make profitability extremely vulnerable — this business needs scale or pricing power urgently. Revenue consistency is the one bright spot — zero dips in five years shows operational resilience. RSI stands at 28, well into oversold territory. Yet sellers still dominated on 19 of recent sessions versus 11 for buyers, so the pressure has not fully lifted. Revenue grows at 15.3% and the stock moves sideways over three months. Neither side makes a strong case. The next earnings print will likely break this stock out of its current range. Check Fundamentals of Biocon Limited.

Biocon Limited (NSE: BIOCON), an innovation-led global biopharmaceuticals company, announced its consolidated financial results for the fiscal second quarter ended September 30, 2026. The company reported total income of Rs 4,423 crore, up 1% year-on-year (YoY). The consolidated operating revenue increased 2% YoY to Rs 4,389 crore.

Financial Performance

Biopharma revenue increased 5% YoY to Rs 3,583 crore. Biosimilars revenue increased 3% YoY to Rs 2,809 crore, while generics revenue increased 10% YoY to Rs 774 crore. Services revenue increased 13% quarter-on-quarter (QoQ) to Rs 833 crore.

Leadership Comments

Kiran Mazumdar-Shaw, Executive Chairperson, Biocon Limited, stated, ‘Biocon continued to achieve industry firsts in biosimilars, with our Pertuzumab becoming the first monoclonal antibody biosimilar recommended under the EMA’s new tailored clinical development pathway.’ Shreehas Tambe, CEO & Managing Director, Biocon Limited, added, ‘We are well positioned for growth in the second half of FY27, with the upcoming European launch of Pertuzumab and expanded insulin manufacturing capacity in Malaysia to support growing U.S. demand.’

As a result, Biocon Limited is confident in its long-term growth trajectory, driven by strategic milestones and continued investments in technology and innovation.

Source: NSE Corporate Announcement

Fundamental & Technical Analysis of Biocon Limited

Biocon Limited belongs to the Healthcare › Biotechnology sector. Here’s a quick read on where the business and the stock stand today.

Biocon drops 20.1% over three months and trades near its 52-week lows. Razor-thin margins below 5% make profitability extremely vulnerable — this business needs scale or pricing power urgently. Revenue consistency is the one bright spot — zero dips in five years shows operational resilience. RSI stands at 28, well into oversold territory. Yet sellers still dominated on 19 of recent sessions versus 11 for buyers, so the pressure has not fully lifted. Revenue grows at 15.3% and the stock moves sideways over three months. Neither side makes a strong case. The next earnings print will likely break this stock out of its current range. Check Fundamentals of Biocon Limited.

Anthem Biosciences Limited (NSE: ANTHEM) has announced robust financial results for the second quarter and half year of FY27, showcasing significant growth and margin expansion. Consolidated revenue from operations for the quarter stood at ₹5,940 Mn, up 7.9% YoY, while EBITDA was ₹3,304 Mn, marking a 24.1% increase. The company’s profit after tax (PAT) for Q2FY27 was ₹2,115 Mn, reflecting a 21.9% rise compared to the same period last year.

Half-Year Financial Highlights

For the first half of FY27, Anthem Biosciences Limited reported consolidated revenue from operations of ₹10,123 Mn, a decrease of 7.2% YoY. However, the company’s EBITDA for H1 FY27 was ₹5,059 Mn, with margins at 46.2%. The PAT for H1 FY27 was ₹3,314 Mn, showing a 7.2% increase compared to H1 FY26.

Margin and Cost Efficiency

Anthem Biosciences Limited has demonstrated strong performance in maintaining and expanding its EBITDA and PAT margins. The company’s ability to sustain growth is attributed to strict discipline around cost efficiencies, yield optimization, and workforce productivity. This has further solidified its industry-leading margins, positioning the company well to sustain this performance throughout the year.

Source: NSE Corporate Announcement

Fundamental & Technical Analysis of Anthem Biosciences Limited

Anthem Biosciences Limited belongs to the Healthcare › Biotechnology sector. Here’s a quick read on where the business and the stock stand today.

Anthem posts a 5.8% three-month gain, but softens in the last few weeks. The PEG stands at 5.22 — severely stretched. Any earnings miss could trigger a sharp de-rating. Industry-leading margins of 28.7% reflect exceptional pricing power and operational efficiency. The stock gives back 9.5% in the last month despite a positive three-month run. As a result, the earlier momentum appears to be fading. The business grows revenue at 26.2% and profits at 15.4%, with D/E of 0.00. The stock reflects that strength. Moreover, when fundamentals and price action align, the PEG of 5.22 premium is usually justified. Check Fundamentals of Anthem Biosciences Limited.